PROCARE - PROstate Cancer Real World Evidence Registry
Launched by UROTRIALS COMPANY (GMBH) · Feb 13, 2025
Trial Information
Current as of July 09, 2025
Recruiting
Keywords
ClinConnect Summary
The PROCARE study is a clinical trial aimed at understanding the treatment and progression of prostate cancer in patients with different stages of the disease. Specifically, it focuses on men who have experienced a rise in their PSA levels after previous treatments, such as surgery or radiation. This includes those with prostate cancer that has returned but hasn’t spread, those whose cancer has spread but is still responding to hormone therapy, and those whose cancer continues to progress despite hormone treatment. By gathering information from these various patient groups, researchers hope to better understand how to manage and treat prostate cancer over the long term.
To participate in this study, patients must be at least 18 years old and have been diagnosed with one of the specific types of prostate cancer mentioned. They should also be starting a new treatment for their cancer or have done so within the last four weeks. Participants will be monitored regularly to track their treatment and health outcomes. This study is currently recruiting, so if you or a loved one are eligible, you may have the opportunity to contribute to important research that could benefit future prostate cancer patients.
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • Adult prostate cancer patients (age ≥18 years).
- • Diagnosis at time of study inclusion Cohort 1: biochemical recurrence (BCR) after local curative intended treatment (e.g. radical prostatectomy, radiotherapy of the prostate or combination thereof) Cohort 2: non-metastatic castration-resistant prostate cancer (nmCRPC) or Cohort 3: metastatic hormone sensitive prostate cancer (mHSPC) or Cohort 4: metastatic castration-resistant prostate cancer (mCRPC) (irrespective of treatment choice, treatment line)
- • Patients who will receive a new line of systemic therapy at the time of study entry or up to 4 weeks thereafter. Regarding Cohort 4 this includes patients with a new diagnosis of mCRPC (=first line mCRPC) after either treatment for mHSPC or non-metastatic CRPC as well as patients with prior mCRPC treatments (2nd, 3rd, ... line).
- • For Cohorts 1, 2 and 3: Disease proven by clinical measures (i.e. standard imaging) to be either unsuitable for local salvage treatment (e.g. surgery, radiotherapy) or local treatment is declined by the patient.
- • Patients, who are able and willing to sign the informed consent form
- Exclusion Criteria:
- • • Patients who are not eligible for observation due to severe comorbidities or unavailability according to the treating physician
About Urotrials Company (Gmbh)
UroTrials Company (GmbH) is a specialized clinical trial sponsor dedicated to advancing innovative therapies within the field of urology. With a strong focus on enhancing patient care, UroTrials collaborates with leading researchers and healthcare institutions to design and conduct rigorous clinical studies. The company is committed to adhering to the highest ethical standards and regulatory requirements, ensuring the integrity of its trials while fostering a patient-centric approach. Through its expertise in urological research, UroTrials aims to contribute significantly to the development of effective treatments and improve outcomes for patients with urological conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hamburg, , Germany
Ulm, , Germany
Tübingen, , Germany
Würzburg, Bavaria, Germany
Tübingen, Baden Württemberg, Germany
Jena, Thuringia, Germany
Ulm, Baden Württemberg, Germany
Magdeburg, Saxony Anhalt, Germany
Bonn, North Rhine Westphalia, Germany
Augsburg, Bavaria, Germany
Leipzig, Saxony, Germany
Bayreuth, Bavaria, Germany
Nürnberg, Bavaria, Germany
Gießen, Hesse, Germany
Marburg, Hesse, Germany
Wetzlar, Hesse, Germany
Braunschweig, Lower Saxony, Germany
Herzberg, Lower Saxony, Germany
Wilhelmshaven, Lower Saxony, Germany
Bayenthal, North Rhine Westphalia, Germany
Bergisch Gladbach, North Rhine Westphalia, Germany
Duisburg, North Rhine Westphalia, Germany
Essen, North Rhine Westphalia, Germany
Herne, North Rhine Westphalia, Germany
Paderborn, North Rhine Westphalia, Germany
Wuppertal, North Rhine Westphalia, Germany
Würselen, North Rhine Westphalia, Germany
Trier, Rhineland Palatinate, Germany
Neunkirchen, Saarland, Germany
Lübeck, Schleswig Holstein, Germany
Berlin, Brandenburg, Germany
Karlsruhe, Rhineland Palatinate, Germany
Heidelberg, Baden Württemberg, Germany
Nürtingen, Baden Württemberg, Germany
Hildesheim, Lower Saxony, Germany
Magdeburg, Lower Saxony, Germany
Rostock, Mecklenburg Western Pomerania, Germany
Bonn, North Rhine Westphalia, Germany
Halle, Saxony Anhalt, Germany
Heidelberg, , Germany
Nürtingen, , Germany
Patients applied
Trial Officials
Marc-Oliver Grimm, Professor
Study Director
University Hospital Jena
Boris Hadaschik, Professor
Study Director
University Hospital, Essen
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported